Eukaryotic ADCY7 catalyzes the production of c-di-AMP to activate the NLRP3 inflammasome
Toll-like receptor 9 (TLR9) agonists cause activation of nucleotide-binding domain, leucine-rich repeat protein 3 (NLRP3) inflammasomes but the mechanism is not clear. We found that there is a second signal downstream of TLR9 that induces NLRP3 inflammasome activation. Through screening, adenylate c...
Saved in:
Published in | Nature chemical biology Vol. 21; no. 8; pp. 1283 - 1291 |
---|---|
Main Authors | , , , , , , , , , , , , , , , , |
Format | Journal Article |
Language | English |
Published |
New York
Nature Publishing Group US
01.08.2025
Nature Publishing Group |
Subjects | |
Online Access | Get full text |
Cover
Loading…
Abstract | Toll-like receptor 9 (TLR9) agonists cause activation of nucleotide-binding domain, leucine-rich repeat protein 3 (NLRP3) inflammasomes but the mechanism is not clear. We found that there is a second signal downstream of TLR9 that induces NLRP3 inflammasome activation. Through screening, adenylate cyclase 7 (ADCY7) was found to be an essential regulator of this process. In cells with
Adcy7
deficiency, TLR9 agonists were no longer able to activate the NLRP3 inflammasome. ADCY7 not only catalyzes the generation of cyclic adenosine monophosphate (cAMP) but also catalyzes the synthesis of its dimeric form (c-di-AMP). Moreover, c-di-AMP promotes assembly and maturation of the inflammasome by directly binding to NLRP3. Cells with
Adcy7
deletion or mutations impacting enzymatic activity cannot produce c-di-AMP. The survival of
Adcy7
-deficient mice in acute liver injury was also improved. In summary, we found that ADCY7 is required for NLRP3 inflammasome activation downstream of TLR9 by catalyzing the generation of c-di-AMP, which may serve as a target for controlling inflammatory responses in sterile infections.
Cyclic dimeric adenosine monophosphate is found to be a second messenger in eukaryotic cells that is generated by adenylate cyclase 7 and connects Toll-like receptor 9 stimulation to nucleotide-binding domain, leucine-rich repeat protein 3 inflammasome activation. |
---|---|
AbstractList | Toll-like receptor 9 (TLR9) agonists cause activation of nucleotide-binding domain, leucine-rich repeat protein 3 (NLRP3) inflammasomes but the mechanism is not clear. We found that there is a second signal downstream of TLR9 that induces NLRP3 inflammasome activation. Through screening, adenylate cyclase 7 (ADCY7) was found to be an essential regulator of this process. In cells with
Adcy7
deficiency, TLR9 agonists were no longer able to activate the NLRP3 inflammasome. ADCY7 not only catalyzes the generation of cyclic adenosine monophosphate (cAMP) but also catalyzes the synthesis of its dimeric form (c-di-AMP). Moreover, c-di-AMP promotes assembly and maturation of the inflammasome by directly binding to NLRP3. Cells with
Adcy7
deletion or mutations impacting enzymatic activity cannot produce c-di-AMP. The survival of
Adcy7
-deficient mice in acute liver injury was also improved. In summary, we found that ADCY7 is required for NLRP3 inflammasome activation downstream of TLR9 by catalyzing the generation of c-di-AMP, which may serve as a target for controlling inflammatory responses in sterile infections.
Cyclic dimeric adenosine monophosphate is found to be a second messenger in eukaryotic cells that is generated by adenylate cyclase 7 and connects Toll-like receptor 9 stimulation to nucleotide-binding domain, leucine-rich repeat protein 3 inflammasome activation. Toll-like receptor 9 (TLR9) agonists cause activation of nucleotide-binding domain, leucine-rich repeat protein 3 (NLRP3) inflammasomes but the mechanism is not clear. We found that there is a second signal downstream of TLR9 that induces NLRP3 inflammasome activation. Through screening, adenylate cyclase 7 (ADCY7) was found to be an essential regulator of this process. In cells with Adcy7 deficiency, TLR9 agonists were no longer able to activate the NLRP3 inflammasome. ADCY7 not only catalyzes the generation of cyclic adenosine monophosphate (cAMP) but also catalyzes the synthesis of its dimeric form (c-di-AMP). Moreover, c-di-AMP promotes assembly and maturation of the inflammasome by directly binding to NLRP3. Cells with Adcy7 deletion or mutations impacting enzymatic activity cannot produce c-di-AMP. The survival of Adcy7-deficient mice in acute liver injury was also improved. In summary, we found that ADCY7 is required for NLRP3 inflammasome activation downstream of TLR9 by catalyzing the generation of c-di-AMP, which may serve as a target for controlling inflammatory responses in sterile infections.Toll-like receptor 9 (TLR9) agonists cause activation of nucleotide-binding domain, leucine-rich repeat protein 3 (NLRP3) inflammasomes but the mechanism is not clear. We found that there is a second signal downstream of TLR9 that induces NLRP3 inflammasome activation. Through screening, adenylate cyclase 7 (ADCY7) was found to be an essential regulator of this process. In cells with Adcy7 deficiency, TLR9 agonists were no longer able to activate the NLRP3 inflammasome. ADCY7 not only catalyzes the generation of cyclic adenosine monophosphate (cAMP) but also catalyzes the synthesis of its dimeric form (c-di-AMP). Moreover, c-di-AMP promotes assembly and maturation of the inflammasome by directly binding to NLRP3. Cells with Adcy7 deletion or mutations impacting enzymatic activity cannot produce c-di-AMP. The survival of Adcy7-deficient mice in acute liver injury was also improved. In summary, we found that ADCY7 is required for NLRP3 inflammasome activation downstream of TLR9 by catalyzing the generation of c-di-AMP, which may serve as a target for controlling inflammatory responses in sterile infections. Toll-like receptor 9 (TLR9) agonists cause activation of nucleotide-binding domain, leucine-rich repeat protein 3 (NLRP3) inflammasomes but the mechanism is not clear. We found that there is a second signal downstream of TLR9 that induces NLRP3 inflammasome activation. Through screening, adenylate cyclase 7 (ADCY7) was found to be an essential regulator of this process. In cells with Adcy7 deficiency, TLR9 agonists were no longer able to activate the NLRP3 inflammasome. ADCY7 not only catalyzes the generation of cyclic adenosine monophosphate (cAMP) but also catalyzes the synthesis of its dimeric form (c-di-AMP). Moreover, c-di-AMP promotes assembly and maturation of the inflammasome by directly binding to NLRP3. Cells with Adcy7 deletion or mutations impacting enzymatic activity cannot produce c-di-AMP. The survival of Adcy7-deficient mice in acute liver injury was also improved. In summary, we found that ADCY7 is required for NLRP3 inflammasome activation downstream of TLR9 by catalyzing the generation of c-di-AMP, which may serve as a target for controlling inflammatory responses in sterile infections. Toll-like receptor 9 (TLR9) agonists cause activation of nucleotide-binding domain, leucine-rich repeat protein 3 (NLRP3) inflammasomes but the mechanism is not clear. We found that there is a second signal downstream of TLR9 that induces NLRP3 inflammasome activation. Through screening, adenylate cyclase 7 (ADCY7) was found to be an essential regulator of this process. In cells with Adcy7 deficiency, TLR9 agonists were no longer able to activate the NLRP3 inflammasome. ADCY7 not only catalyzes the generation of cyclic adenosine monophosphate (cAMP) but also catalyzes the synthesis of its dimeric form (c-di-AMP). Moreover, c-di-AMP promotes assembly and maturation of the inflammasome by directly binding to NLRP3. Cells with Adcy7 deletion or mutations impacting enzymatic activity cannot produce c-di-AMP. The survival of Adcy7-deficient mice in acute liver injury was also improved. In summary, we found that ADCY7 is required for NLRP3 inflammasome activation downstream of TLR9 by catalyzing the generation of c-di-AMP, which may serve as a target for controlling inflammatory responses in sterile infections.Cyclic dimeric adenosine monophosphate is found to be a second messenger in eukaryotic cells that is generated by adenylate cyclase 7 and connects Toll-like receptor 9 stimulation to nucleotide-binding domain, leucine-rich repeat protein 3 inflammasome activation. |
Author | Wang, Shuo Bai, Lin Qian, Yan Kong, Chun Ren, Chao Liu, Xiaoyun Geng, Xiangyang Liu, Qiannv Cheng, Xiangyun Xia, Pengyan Wang, Chunlei Jiang, Dong Li, Mengqian Wang, Lin Zhang, Yan Wang, Kai Tang, Zhiheng |
Author_xml | – sequence: 1 givenname: Qiannv surname: Liu fullname: Liu, Qiannv organization: Department of Immunology, School of Basic Medical Sciences, Peking University, NHC Key Laboratory of Medical Immunology, Peking University, Medicine Innovation Center for Fundamental Research on Major Immunology-Related Diseases, Peking University – sequence: 2 givenname: Zhiheng surname: Tang fullname: Tang, Zhiheng organization: NHC Key Laboratory of Medical Immunology, Peking University, Department of Microbiology and Infectious Disease Center, School of Basic Medical Sciences, Peking University – sequence: 3 givenname: Yan surname: Qian fullname: Qian, Yan organization: Department of Immunology, School of Basic Medical Sciences, Peking University, NHC Key Laboratory of Medical Immunology, Peking University, Medicine Innovation Center for Fundamental Research on Major Immunology-Related Diseases, Peking University – sequence: 4 givenname: Chunlei surname: Wang fullname: Wang, Chunlei organization: Department of Immunology, School of Basic Medical Sciences, Peking University, NHC Key Laboratory of Medical Immunology, Peking University, Medicine Innovation Center for Fundamental Research on Major Immunology-Related Diseases, Peking University – sequence: 5 givenname: Chun surname: Kong fullname: Kong, Chun organization: Department of Immunology, School of Basic Medical Sciences, Peking University, NHC Key Laboratory of Medical Immunology, Peking University, Medicine Innovation Center for Fundamental Research on Major Immunology-Related Diseases, Peking University – sequence: 6 givenname: Mengqian surname: Li fullname: Li, Mengqian organization: Department of Immunology, School of Basic Medical Sciences, Peking University, NHC Key Laboratory of Medical Immunology, Peking University, Medicine Innovation Center for Fundamental Research on Major Immunology-Related Diseases, Peking University – sequence: 7 givenname: Xiangyang surname: Geng fullname: Geng, Xiangyang organization: Department of Immunology, School of Basic Medical Sciences, Peking University, NHC Key Laboratory of Medical Immunology, Peking University, Medicine Innovation Center for Fundamental Research on Major Immunology-Related Diseases, Peking University – sequence: 8 givenname: Yan surname: Zhang fullname: Zhang, Yan organization: Department of Immunology, School of Basic Medical Sciences, Peking University, NHC Key Laboratory of Medical Immunology, Peking University, Medicine Innovation Center for Fundamental Research on Major Immunology-Related Diseases, Peking University – sequence: 9 givenname: Xiangyun surname: Cheng fullname: Cheng, Xiangyun organization: Department of Sports Medicine, Peking University Third Hospital, Beijing Key Laboratory of Sports Injuries, Institute of Sports Medicine of Peking University – sequence: 10 givenname: Chao surname: Ren fullname: Ren, Chao organization: Department of Respiratory and Critical Care Medicine, Beijing Institute of Respiratory Medicine, Beijing Chao-Yang Hospital, Capital Medical University – sequence: 11 givenname: Kai surname: Wang fullname: Wang, Kai organization: Department of Immunology, School of Basic Medical Sciences, Peking University, NHC Key Laboratory of Medical Immunology, Peking University, Medicine Innovation Center for Fundamental Research on Major Immunology-Related Diseases, Peking University – sequence: 12 givenname: Lin surname: Bai fullname: Bai, Lin organization: Department of Biophysics, School of Basic Medical Sciences, Peking University – sequence: 13 givenname: Lin orcidid: 0000-0003-1555-9985 surname: Wang fullname: Wang, Lin organization: Department of Microbiology and Infectious Disease Center, School of Basic Medical Sciences, Peking University – sequence: 14 givenname: Dong surname: Jiang fullname: Jiang, Dong organization: Department of Sports Medicine, Peking University Third Hospital, Beijing Key Laboratory of Sports Injuries, Institute of Sports Medicine of Peking University – sequence: 15 givenname: Shuo orcidid: 0000-0002-5383-3386 surname: Wang fullname: Wang, Shuo email: wangshuo@im.ac.cn organization: CAS Key Laboratory of Pathogen Microbiology and Immunology, Institute of Microbiology, Chinese Academy of Sciences – sequence: 16 givenname: Xiaoyun orcidid: 0000-0001-7083-5263 surname: Liu fullname: Liu, Xiaoyun email: xiaoyun.liu@bjmu.edu.cn organization: NHC Key Laboratory of Medical Immunology, Peking University, Department of Microbiology and Infectious Disease Center, School of Basic Medical Sciences, Peking University, Department of Infectious Diseases, Peking University Third Hospital – sequence: 17 givenname: Pengyan orcidid: 0000-0001-7959-5796 surname: Xia fullname: Xia, Pengyan email: xiap@pku.edu.cn organization: Department of Immunology, School of Basic Medical Sciences, Peking University, NHC Key Laboratory of Medical Immunology, Peking University, Medicine Innovation Center for Fundamental Research on Major Immunology-Related Diseases, Peking University, PUHSC Primary Immunodeficiency Research Center, Peking University |
BackLink | https://www.ncbi.nlm.nih.gov/pubmed/40419769$$D View this record in MEDLINE/PubMed |
BookMark | eNp9kUtPxCAUhYnR-Bj9Ay4MiRs3KBcKtMvJ-EzGR4wLXRGGglbboqU1GX-96PhIXJi74IZ8h3u4ZwMtt6F1CG0D3QfK84OYgcgLQpkgFAooyHwJrYMQjGSZLJZ_ekHX0EaMj5RyKSFfRWsZzaBQslhHt0fDk-nmoa8sHh9O7hS2pjf1_M1F3D84_NyFcrB9FVocPLakrMj4_Ar3AZt0-2p694ldTK-vOK5aX5umMTE0bhOteFNHt_V1jtDN8dHN5JRML0_OJuMpsZzlPQGfyZnMuS-EUmCk51Lk3JQgvfOqKFnJS5uDZGYG4HOmqOV8ZgRVyklT8hHaWzybjL4MLva6qaJ1dW1aF4aoOYOPUunvI7T7B30MQ9cmc4niGQAVjCVq54saZo0r9XNXNWlB-ntlCWALwHYhxs75HwSo_shFL3LRKRf9mYueJxFfiGKC23vX_c7-R_UOTVONzA |
Cites_doi | 10.1038/s41590-021-00886-5 10.1111/j.1471-4159.1993.tb05852.x 10.1007/s00125-014-3437-z 10.1016/j.immuni.2017.06.020 10.1038/s41580-020-0244-x 10.1128/mBio.00018-13 10.3389/fimmu.2023.1151185 10.1016/j.tim.2017.09.003 10.1016/j.immuni.2022.10.021 10.1016/S0165-6147(99)01307-3 10.1039/C2CS35206K 10.1016/j.cell.2021.09.019 10.1038/s41564-020-0777-y 10.1021/cr300011s 10.1038/s41589-024-01569-6 10.1146/annurev-micro-032521-024017 10.1007/112_2020_55 10.4049/jimmunol.0901363 10.1159/000166277 10.7554/eLife.99939.3 10.1146/annurev-pathmechdis-032521-102529 10.1097/00000658-197511000-00012 10.1038/nature11588 10.1016/j.coph.2018.05.012 10.1074/jbc.M803281200 10.1016/j.cell.2023.05.038 10.1021/acs.jmedchem.9b01062 10.1016/j.addr.2008.12.008 10.1146/annurev-immunol-081022-021207 10.1038/embor.2013.132 10.1016/j.immuni.2018.04.032 10.1038/s41577-019-0165-0 10.2147/JIR.S464838 10.3389/fonc.2022.829212 10.1038/nri3452 10.1038/374546a0 10.1038/s41423-022-00922-w 10.1146/annurev-immunol-032713-120156 10.1038/nature08780 10.1038/s41423-024-01221-2 10.1124/pr.116.013078 10.1186/s13045-024-01524-x 10.1186/s12987-022-00322-2 |
ContentType | Journal Article |
Copyright | The Author(s), under exclusive licence to Springer Nature America, Inc. 2025 Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law. 2025. The Author(s), under exclusive licence to Springer Nature America, Inc. The Author(s), under exclusive licence to Springer Nature America, Inc. 2025 |
Copyright_xml | – notice: The Author(s), under exclusive licence to Springer Nature America, Inc. 2025 Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law. – notice: 2025. The Author(s), under exclusive licence to Springer Nature America, Inc. – notice: The Author(s), under exclusive licence to Springer Nature America, Inc. 2025 |
DBID | AAYXX CITATION CGR CUY CVF ECM EIF NPM 7QL 7QP 7QR 7TK 7TM 7U9 8FD C1K FR3 H94 K9. M7N P64 RC3 7X8 |
DOI | 10.1038/s41589-025-01919-y |
DatabaseName | CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed Bacteriology Abstracts (Microbiology B) Calcium & Calcified Tissue Abstracts Chemoreception Abstracts Neurosciences Abstracts Nucleic Acids Abstracts Virology and AIDS Abstracts Technology Research Database Environmental Sciences and Pollution Management Engineering Research Database AIDS and Cancer Research Abstracts ProQuest Health & Medical Complete (Alumni) Algology Mycology and Protozoology Abstracts (Microbiology C) Biotechnology and BioEngineering Abstracts Genetics Abstracts MEDLINE - Academic |
DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) Virology and AIDS Abstracts Technology Research Database Nucleic Acids Abstracts ProQuest Health & Medical Complete (Alumni) Neurosciences Abstracts Biotechnology and BioEngineering Abstracts Environmental Sciences and Pollution Management Genetics Abstracts Bacteriology Abstracts (Microbiology B) Algology Mycology and Protozoology Abstracts (Microbiology C) AIDS and Cancer Research Abstracts Chemoreception Abstracts Engineering Research Database Calcium & Calcified Tissue Abstracts MEDLINE - Academic |
DatabaseTitleList | MEDLINE - Academic MEDLINE Virology and AIDS Abstracts |
Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Anatomy & Physiology Chemistry |
EISSN | 1552-4469 |
EndPage | 1291 |
ExternalDocumentID | 40419769 10_1038_s41589_025_01919_y |
Genre | Journal Article |
GrantInformation_xml | – fundername: the National Key R&D Program of China (2021YFA1300202, 2022YFC2302900 and 2022YFA1304500), Strategic Priority Research Programs of the Chinese Academy of Sciences (XDB29020000), Key Research Program of Frontier Sciences of Chinese Academy of Sciences (ZDBS-LY-SM025), CAS Project for Young Scientists in Basic Research (YSBR-010) – fundername: Natural Science Foundation of Beijing Municipality (Beijing Natural Science Foundation) grantid: JG23028 funderid: https://doi.org/10.13039/501100004826 – fundername: Youth Innovation Promotion Association of the Chinese Academy of Sciences (Youth Innovation Promotion Association CAS) funderid: https://doi.org/10.13039/501100004739 – fundername: National Natural Science Foundation of China (National Science Foundation of China) grantid: 92369104, 82271790, 92169113, 22174003; 92369104; 92369104; 92369104; 82271790; 82271790; 82271790; 92369104; 92169113; 82271790; 82271790; 82271790; 82271790; 92369104; 92369104; 92369104; 92169113 funderid: https://doi.org/10.13039/501100001809 – fundername: Fok Ying Tung Education Foundation (FYTEF) funderid: https://doi.org/10.13039/501100010261 – fundername: Natural Science Foundation of Beijing Municipality (Beijing Natural Science Foundation) grantid: JG23028 – fundername: National Natural Science Foundation of China (National Science Foundation of China) grantid: 92369104 – fundername: National Natural Science Foundation of China (National Science Foundation of China) grantid: 92369104, 82271790, 92169113, 22174003 – fundername: National Natural Science Foundation of China (National Science Foundation of China) grantid: 92169113 – fundername: National Natural Science Foundation of China (National Science Foundation of China) grantid: 82271790 |
GroupedDBID | --- 0R~ 123 29M 39C 4.4 53G 70F 7X7 88E 88I 8AO 8FE 8FG 8FH 8FI 8FJ 8R4 8R5 AARCD AAYZH ABAWZ ABDBF ABFSG ABJCF ABJNI ABLJU ABUWG ACBWK ACGFS ACGOD ACIWK ACPRK ACSTC ACUHS ADBBV ADXHL AENEX AEUYN AEZWR AFANA AFBBN AFHIU AFKRA AFRAH AFSHS AGAYW AHBCP AHMBA AHOSX AHSBF AHWEU AIBTJ AIXLP ALFFA ALIPV ALMA_UNASSIGNED_HOLDINGS ALPWD ARMCB ASPBG ATHPR AVWKF AXYYD AZFZN AZQEC BBNVY BENPR BGLVJ BHPHI BKKNO BKSAR BPHCQ BVXVI CCPQU CS3 CZ9 D1I DB5 DU5 DWQXO EBS EE. EJD EMOBN ESX EXGXG F5P FEDTE FQGFK FSGXE FYUFA GNUQQ HCIFZ HMCUK HVGLF HZ~ KB. KC. LK5 LK8 M1P M2P M7P M7R NACWA NFIDA NNMJJ O9- ODYON P2P PCBAR PDBOC PHGZM PHGZT PJZUB PPXIY PQGLB PQQKQ PROAC PSQYO Q2X RNT RNTTT SHXYY SIXXV SJN SNYQT SOJ SV3 TAOOD TBHMF TDRGL TSG TUS UKHRP ~8M AAYXX CITATION CGR CUY CVF ECM EIF NPM 7QL 7QP 7QR 7TK 7TM 7U9 8FD C1K FR3 H94 K9. M7N P64 RC3 7X8 |
ID | FETCH-LOGICAL-c328t-1f46b683f95771a6f36583ad16fef79d2d3dc8162ab11f8270c33ba5077e6ad3 |
ISSN | 1552-4450 1552-4469 |
IngestDate | Wed Jul 02 02:53:39 EDT 2025 Sat Aug 23 13:27:10 EDT 2025 Mon Aug 04 01:30:42 EDT 2025 Thu Aug 07 05:34:10 EDT 2025 Tue Jul 29 01:10:27 EDT 2025 |
IsPeerReviewed | true |
IsScholarly | true |
Issue | 8 |
Language | English |
License | 2025. The Author(s), under exclusive licence to Springer Nature America, Inc. |
LinkModel | OpenURL |
MergedId | FETCHMERGED-LOGICAL-c328t-1f46b683f95771a6f36583ad16fef79d2d3dc8162ab11f8270c33ba5077e6ad3 |
Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 content type line 23 |
ORCID | 0000-0003-1555-9985 0000-0001-7083-5263 0000-0002-5383-3386 0000-0001-7959-5796 |
PMID | 40419769 |
PQID | 3234110522 |
PQPubID | 29034 |
PageCount | 9 |
ParticipantIDs | proquest_miscellaneous_3212121700 proquest_journals_3234110522 pubmed_primary_40419769 crossref_primary_10_1038_s41589_025_01919_y springer_journals_10_1038_s41589_025_01919_y |
PublicationCentury | 2000 |
PublicationDate | 20250800 |
PublicationDateYYYYMMDD | 2025-08-01 |
PublicationDate_xml | – month: 8 year: 2025 text: 20250800 |
PublicationDecade | 2020 |
PublicationPlace | New York |
PublicationPlace_xml | – name: New York – name: United States – name: Cambridge |
PublicationTitle | Nature chemical biology |
PublicationTitleAbbrev | Nat Chem Biol |
PublicationTitleAlternate | Nat Chem Biol |
PublicationYear | 2025 |
Publisher | Nature Publishing Group US Nature Publishing Group |
Publisher_xml | – name: Nature Publishing Group US – name: Nature Publishing Group |
References | A Di (1919_CR39) 2018; 49 W Gu (1919_CR7) 2024; 17 JR Barker (1919_CR29) 2013; 4 KP Hopfner (1919_CR41) 2020; 21 A Akbal (1919_CR37) 2022; 19 W Li (1919_CR45) 2024; 20 WF Simonds (1919_CR23) 1999; 20 Q Liu (1919_CR43) 2024; 21 J Sanchez-Collado (1919_CR17) 2021; 179 H Dou (1919_CR20) 2015; 58 LI Jiang (1919_CR16) 2008; 283 KC Lam (1919_CR30) 2021; 184 A Millman (1919_CR42) 2020; 5 J Wu (1919_CR33) 2014; 32 KV Swanson (1919_CR35) 2019; 19 AM Krieg (1919_CR10) 1995; 374 JM Blander (1919_CR34) 2018; 41 B Novotná (1919_CR32) 2019; 62 ML Steer (1919_CR15) 1975; 182 GS Lee (1919_CR25) 2012; 492 CW Dessauer (1919_CR22) 2017; 69 BI Herrmann (1919_CR6) 2023; 77 FG Bauernfeind (1919_CR8) 2009; 183 R Sadana (1919_CR21) 2009; 17 Q Zhang (1919_CR13) 2010; 464 KSG de Sá (1919_CR5) 2023; 14 E Latz (1919_CR4) 2013; 13 AA Abdul-Sater (1919_CR26) 2013; 14 R Guo (1919_CR14) 2022; 12 Y Qian (1919_CR44) 2025; 13 K Devasani (1919_CR18) 2022; 19 M de Carvalho Ribeiro (1919_CR2) 2022; 17 NA Schmacke (1919_CR38) 2022; 55 P Clivio (1919_CR40) 2013; 113 J Fu (1919_CR1) 2023; 41 AB Imaeda (1919_CR12) 2009; 119 FM Commichau (1919_CR27) 2018; 26 Y Li (1919_CR31) 2023; 186 D Kalia (1919_CR28) 2013; 42 Z Xia (1919_CR19) 1993; 60 H Zhang (1919_CR24) 2024; 17 J Vollmer (1919_CR11) 2009; 61 BR Sharma (1919_CR3) 2021; 22 X Zheng (1919_CR9) 2023; 14 F Di Virgilio (1919_CR36) 2017; 47 |
References_xml | – volume: 22 start-page: 550 year: 2021 ident: 1919_CR3 publication-title: Nat. Immunol. doi: 10.1038/s41590-021-00886-5 – volume: 60 start-page: 305 year: 1993 ident: 1919_CR19 publication-title: J. Neurochem. doi: 10.1111/j.1471-4159.1993.tb05852.x – volume: 58 start-page: 324 year: 2015 ident: 1919_CR20 publication-title: Diabetologia doi: 10.1007/s00125-014-3437-z – volume: 47 start-page: 15 year: 2017 ident: 1919_CR36 publication-title: Immunity doi: 10.1016/j.immuni.2017.06.020 – volume: 21 start-page: 501 year: 2020 ident: 1919_CR41 publication-title: Nat. Rev. Mol. Cell Biol. doi: 10.1038/s41580-020-0244-x – volume: 4 start-page: e00018-13 year: 2013 ident: 1919_CR29 publication-title: mBio doi: 10.1128/mBio.00018-13 – volume: 14 start-page: 1151185 year: 2023 ident: 1919_CR9 publication-title: Front. Immunol. doi: 10.3389/fimmu.2023.1151185 – volume: 26 start-page: 175 year: 2018 ident: 1919_CR27 publication-title: Trends Microbiol. doi: 10.1016/j.tim.2017.09.003 – volume: 55 start-page: 2271 year: 2022 ident: 1919_CR38 publication-title: Immunity doi: 10.1016/j.immuni.2022.10.021 – volume: 20 start-page: 66 year: 1999 ident: 1919_CR23 publication-title: Trends Pharmacol. Sci. doi: 10.1016/S0165-6147(99)01307-3 – volume: 42 start-page: 305 year: 2013 ident: 1919_CR28 publication-title: Chem. Soc. Rev. doi: 10.1039/C2CS35206K – volume: 184 start-page: 5338 year: 2021 ident: 1919_CR30 publication-title: Cell. doi: 10.1016/j.cell.2021.09.019 – volume: 5 start-page: 1608 year: 2020 ident: 1919_CR42 publication-title: Nat. Microbiol. doi: 10.1038/s41564-020-0777-y – volume: 113 start-page: 7354 year: 2013 ident: 1919_CR40 publication-title: Chem. Rev. doi: 10.1021/cr300011s – volume: 20 start-page: 1434 year: 2024 ident: 1919_CR45 publication-title: Nat. Chem. Biol. doi: 10.1038/s41589-024-01569-6 – volume: 77 start-page: 451 year: 2023 ident: 1919_CR6 publication-title: Annu. Rev. Microbiol. doi: 10.1146/annurev-micro-032521-024017 – volume: 179 start-page: 73 year: 2021 ident: 1919_CR17 publication-title: Rev. Physiol. Biochem. Pharmacol. doi: 10.1007/112_2020_55 – volume: 183 start-page: 787 year: 2009 ident: 1919_CR8 publication-title: J. Immunol. doi: 10.4049/jimmunol.0901363 – volume: 17 start-page: 5 year: 2009 ident: 1919_CR21 publication-title: Neurosignals doi: 10.1159/000166277 – volume: 13 start-page: RP99939 year: 2025 ident: 1919_CR44 publication-title: eLife doi: 10.7554/eLife.99939.3 – volume: 17 start-page: 345 year: 2022 ident: 1919_CR2 publication-title: Annu. Rev. Pathol. doi: 10.1146/annurev-pathmechdis-032521-102529 – volume: 182 start-page: 603 year: 1975 ident: 1919_CR15 publication-title: Ann. Surg. doi: 10.1097/00000658-197511000-00012 – volume: 492 start-page: 123 year: 2012 ident: 1919_CR25 publication-title: Nature doi: 10.1038/nature11588 – volume: 41 start-page: 128 year: 2018 ident: 1919_CR34 publication-title: Curr. Opin. Pharmacol. doi: 10.1016/j.coph.2018.05.012 – volume: 119 start-page: 305 year: 2009 ident: 1919_CR12 publication-title: J. Clin. Invest. – volume: 283 start-page: 23429 year: 2008 ident: 1919_CR16 publication-title: J. Biol. Chem. doi: 10.1074/jbc.M803281200 – volume: 186 start-page: 3261 year: 2023 ident: 1919_CR31 publication-title: Cell. doi: 10.1016/j.cell.2023.05.038 – volume: 62 start-page: 10676 year: 2019 ident: 1919_CR32 publication-title: J. Med. Chem. doi: 10.1021/acs.jmedchem.9b01062 – volume: 61 start-page: 195 year: 2009 ident: 1919_CR11 publication-title: Adv. Drug Deliv. Rev. doi: 10.1016/j.addr.2008.12.008 – volume: 41 start-page: 301 year: 2023 ident: 1919_CR1 publication-title: Annu. Rev. Immunol. doi: 10.1146/annurev-immunol-081022-021207 – volume: 14 start-page: 900 year: 2013 ident: 1919_CR26 publication-title: EMBO Rep. doi: 10.1038/embor.2013.132 – volume: 49 start-page: 56 year: 2018 ident: 1919_CR39 publication-title: Immunity doi: 10.1016/j.immuni.2018.04.032 – volume: 19 start-page: 477 year: 2019 ident: 1919_CR35 publication-title: Nat. Rev. Immunol. doi: 10.1038/s41577-019-0165-0 – volume: 17 start-page: 3801 year: 2024 ident: 1919_CR7 publication-title: J. Inflamm. Res. doi: 10.2147/JIR.S464838 – volume: 12 start-page: 829212 year: 2022 ident: 1919_CR14 publication-title: Front. Oncol. doi: 10.3389/fonc.2022.829212 – volume: 13 start-page: 397 year: 2013 ident: 1919_CR4 publication-title: Nat. Rev. Immunol. doi: 10.1038/nri3452 – volume: 374 start-page: 546 year: 1995 ident: 1919_CR10 publication-title: Nature doi: 10.1038/374546a0 – volume: 19 start-page: 1201 year: 2022 ident: 1919_CR37 publication-title: Cell. Mol. Immunol. doi: 10.1038/s41423-022-00922-w – volume: 32 start-page: 461 year: 2014 ident: 1919_CR33 publication-title: Annu. Rev. Immunol. doi: 10.1146/annurev-immunol-032713-120156 – volume: 464 start-page: 104 year: 2010 ident: 1919_CR13 publication-title: Nature doi: 10.1038/nature08780 – volume: 21 start-page: 1322 year: 2024 ident: 1919_CR43 publication-title: Cell. Mol. Immunol. doi: 10.1038/s41423-024-01221-2 – volume: 69 start-page: 93 year: 2017 ident: 1919_CR22 publication-title: Pharmacol. Rev. doi: 10.1124/pr.116.013078 – volume: 17 start-page: 5 year: 2024 ident: 1919_CR24 publication-title: J. Hematol. Oncol. doi: 10.1186/s13045-024-01524-x – volume: 14 year: 2023 ident: 1919_CR5 publication-title: Nat. Commun. – volume: 19 start-page: 23 year: 2022 ident: 1919_CR18 publication-title: Fluids Barriers CNS doi: 10.1186/s12987-022-00322-2 |
SSID | ssj0036618 |
Score | 2.4803994 |
Snippet | Toll-like receptor 9 (TLR9) agonists cause activation of nucleotide-binding domain, leucine-rich repeat protein 3 (NLRP3) inflammasomes but the mechanism is... |
SourceID | proquest pubmed crossref springer |
SourceType | Aggregation Database Index Database Publisher |
StartPage | 1283 |
SubjectTerms | 631/250/249 631/250/255 Adenosine monophosphate Adenosine triphosphate Adenylate cyclase Adenylyl Cyclases - deficiency Adenylyl Cyclases - genetics Adenylyl Cyclases - metabolism Agonists Animals Binding Biochemical Engineering Biochemistry Bioorganic Chemistry Catalysis Cell Biology Cell culture Chemical synthesis Chemistry Chemistry and Materials Science Chemistry/Food Science Clonal deletion Cyclic AMP Cytotoxicity Dimers Dinucleoside Phosphates - metabolism Enzymatic activity Gene deletion Genes HEK293 Cells Humans Inflammasomes Inflammasomes - metabolism Leucine Mice Mice, Inbred C57BL Mice, Knockout Mitochondrial DNA Mortality NLR Family, Pyrin Domain-Containing 3 Protein - metabolism Nucleotides Physiology Potassium Proteins TLR9 protein Toll-Like Receptor 9 - agonists Toll-Like Receptor 9 - metabolism Toll-like receptors |
Title | Eukaryotic ADCY7 catalyzes the production of c-di-AMP to activate the NLRP3 inflammasome |
URI | https://link.springer.com/article/10.1038/s41589-025-01919-y https://www.ncbi.nlm.nih.gov/pubmed/40419769 https://www.proquest.com/docview/3234110522 https://www.proquest.com/docview/3212121700 |
Volume | 21 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3fb9MwELbK9gAvCDZghYGMhHgpGYntxuljVzZNiFUDFbHxEjmxrVawBK3JpO6v4E_mbOcX6yYxVCmq3FPi-r74vrPvzgi98VPF_JRoL5KKe0yq0EuAR3hSioDxEKyKNvnOx9Pw6Cv7eDo87fV-d6KWyiLZS69uzCv5H61CG-jVZMneQbPNTaEBvoN-4Qoahus_6fig_CEuVrmpuTr-MDnjA7sYs7oyZRtsBpSt5lpRwtSTC298fGLYpslmuASW6UIcP305oSYqC8BxLpbXyhdMbeXPQVoXFqiqNjWBPIvSaOkzoCy7bJcB3Azyfb6Yq8o0msXVhVttPWsR-a2SnMzL7KdadNcgyLCJgCvqEt6mJ9cXzpoiim5mHRKPMVdldk9129xZLfV07BKmK9hFnbkVLCnt2GkgKsGNNsBVfF8CMzHRYKaz4JOOvFVr8Zo4RLsDT6PYCccgHFvheHUPbRJwPGDm3Bwf7u9Pa-tOgc_Y9Mr671SJWHCX9-uP_JvsrHkwa7vvltTMHqGHlTeCxw5aj1FPZVtoe5yJIj9f4bfYxgdbfW-h-5P6bMBtdNoiD1vk4QZ5GCCFW-ThXOMaebjIcY08K2aRh7vIe4JmhwezyZFXndHhpZREhRdoFiZhRPVoyHkgQk2B0lIhg1ArzUeSSCrTKAiJSIJAR4T7KaWJAC-Eq1BI-hRtZHmmdhAWjCc0lWHCdMp8yRNBtQRnm3NNfEGDPhrUYxn_cpVY4tv110e79XDH1Ru7jCkBzgYOBSF99Lr5GYbObJKJTOWlkQnMh_t-Hz1zamoex3wWAH0f9dG7Wm_tzW_vy_O7ib9AD9p3bBdtFBelegnMt0heVWD8A4-FqCE |
linkProvider | Library Specific Holdings |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Eukaryotic+ADCY7+catalyzes+the+production+of+c-di-AMP+to+activate+the+NLRP3+inflammasome&rft.jtitle=Nature+chemical+biology&rft.au=Liu%2C+Qiannv&rft.au=Tang%2C+Zhiheng&rft.au=Qian%2C+Yan&rft.au=Wang%2C+Chunlei&rft.date=2025-08-01&rft.pub=Nature+Publishing+Group+US&rft.issn=1552-4450&rft.eissn=1552-4469&rft.volume=21&rft.issue=8&rft.spage=1283&rft.epage=1291&rft_id=info:doi/10.1038%2Fs41589-025-01919-y&rft.externalDocID=10_1038_s41589_025_01919_y |
thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1552-4450&client=summon |
thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1552-4450&client=summon |
thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1552-4450&client=summon |